Coya Therapeutics Inc (NASDAQ:COYA) reported positive results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients with Alzheimer's disease. The study showed a significant decrease in the blood levels of proinflammatory cytokines and chemokines, and a statistically significant improvement in cognitive function. The treatment was safe and well tolerated. A Phase 2 study is being conducted at the Houston Methodist Hospital with results anticipated in July 2024. COYA shares are up 2.99% at $4.13.